Overcoming barriers to implementing precision dosing with 5‐Fluorouracil and capecitabine

Dosing based on body surface area has been demonstrated to be imprecise. Approaches such as dihydropyrimidine dehydrogenase (DPD) enzyme activity testing and pharmacokinetic guided dosing can reduce toxicity, but these strategies have not yet been uniformly implemented.

SPS commentary:

In November last year, NHS England published a commissioning policy for pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies.

Source:

British Journal of Clinical Pharmacology

Resource links:

Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies